PRISCILLA YEON: Open Payments
NPI 1861965790 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,906 in 225 payments from 19 companies in 2025. Trend: 2023 $4,169 · 2024 $4,839 · 2025 $5,906
Food & beverage: $4,611Consulting: $1,188Education: $107
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 16 | $1,685 |
| ABBVIE INC. | 25 | $508 |
| UCB, Inc. | 21 | $493 |
| GENZYME CORPORATION | 13 | $486 |
| Galderma Laboratories, L.P. | 22 | $403 |
| Janssen Biotech, Inc. | 24 | $395 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 17 | $274 |
| Incyte Corporation | 15 | $265 |
| Organon LLC | 9 | $241 |
| Botanix SB Inc | 6 | $234 |
Products named: DUPIXENT, Bimzelx, TREMFYA, NEMLUVIO, RINVOQ, OPZELURA, SOFDRA, SKYRIZI.
Industry payments across MD — which companies pay providers there.
